HTG Announces Board of Directors Transition

Rhea-AI Summary

HTG Molecular Diagnostics announced the resignation of Timothy Johnson as Executive Chairman and Board member. Johnson has been a key figure since 2008, previously serving as CEO. His contributions are praised by the current leadership, highlighting his commitment to advancing precision medicine. Dr. Ann Hanham remains the Lead Independent Director, continuing the company's focus on NGS-based molecular profiling and empowering precision medicine through innovative technology.

Positive

• Timothy Johnson's resignation may bring fresh perspectives and new leadership dynamics.
• Continuation of Ann Hanham as Lead Independent Director ensures stability.

Negative

• Departure of a long-standing executive may raise questions about leadership continuity.
• Potential experience gap in strategic decision-making following Johnson's exit.

Timothy Johnson to Retire from the Board; Ann Hanham, Ph.D. Remains Lead Independent Director

TUCSON, Ariz., Jan. 19, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that Timothy (TJ) B. Johnson has resigned his positions as Executive Chairman and a member of HTG’s Board of Directors. Ann F. Hanham, Ph.D. will remain as Lead Independent Director.

Mr. Johnson has served as HTG’s Executive Chairman since March 31, 2019 and as a member of the Company’s Board of Directors since January 2008. Mr. Johnson previously served as the Company’s Chief Executive Officer from January 2008 until his transition to Executive Chairman in March 2019.     

“TJ has been a cornerstone of HTG since 2008. During this time, he has been a passionate advocate for HTG and its mission to advance precision medicine,” said Mr. Lubniewski. “We are grateful for the valuable contributions TJ made to HTG over the years and wish him continued success.”

About HTG:
HTG is focused on NGS-based molecular profiling. The Company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Its mission is to empower precision medicine.

Contact:
Ashley R. Robinson
Phone: (617) 430-7577
Email: arr@lifesciadvisors.com 

 

FAQ

What led to Timothy Johnson's resignation from HTG Molecular Diagnostics?

Timothy Johnson resigned from his positions as Executive Chairman and Board member, ending a significant tenure since 2008, to allow for new leadership.

Who will lead HTG Molecular Diagnostics now that Timothy Johnson has retired?

Ann Hanham, Ph.D., will continue her role as Lead Independent Director, providing leadership continuity.

What was Timothy Johnson's role at HTG Molecular Diagnostics?

Timothy Johnson served as Executive Chairman since March 2019 and previously as CEO from January 2008.

How might Timothy Johnson's departure affect HTG's future?

Johnson's departure could bring new perspectives to HTG's leadership but may also create concerns regarding continuity and strategic direction.